The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced that the Sputnik V vaccine demonstrated efficacy of 97.6%, based on the analysis of data on the infection rate of coronavirus among those in Russia vaccinated with both components of Sputnik V.
The Ministry of Health of Russia maintains a register of persons who have been vaccinated, as well as citizens who have got infected with COVID as part of the Unified State Information System in Healthcare.
According to the data from 3.8 million Russians vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021 as part of the mass-scale civil vaccination program, the infection rate starting from the 35th day from the date of the first injection was only 0.027%.
At the same time, the incidence among the unvaccinated adult population was 1.1% for a comparable period starting from the 35th day after the launch of mass-scale vaccination in Russia.
The following formula was used to calculate the vaccine's efficacy:
The data and calculations of the vaccine’s efficacy will be published in a peer-reviewed medical journal in May.
Sputnik V is approved for use in 60 countries with a total population of 3 billion people. Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.